Young Michael H, Aronoff David M, Engleberg N Cary
Ann Arbor Veterans Affairs Hospital, Division of Infectious Diseases, Department of Internal Medicine, Ann Arbor, MI, USA.
Expert Rev Anti Infect Ther. 2005 Apr;3(2):279-94. doi: 10.1586/14787210.3.2.279.
Necrotizing fasciitis is a rapidly progressive, life-threatening infection and a true infectious disease emergency. Despite much clinical experience, the management of this disease remains suboptimal, with mortality rates remaining approximately 30%. Necrotizing fasciitis rarely presents with obvious signs and symptoms and delays in diagnosis enhance mortality. Therefore, successful patient care depends on the physician's acumen and index of suspicion. Prompt surgical debridement, intravenous antibiotics, fluid and electrolyte management, and analgesia are mainstays of therapy. Adjunctive clindamycin, hyperbaric oxygen therapy and intravenous immunoglobulin are frequently employed in the treatment of necrotizing fasciitis, but their efficacy has not been rigorously established. Improved understanding of the pathogenesis of necrotizing fasciitis has revealed new targets for rationally designed therapies to improve morbidity and mortality.
坏死性筋膜炎是一种进展迅速、危及生命的感染性疾病,是真正的感染性疾病急症。尽管有丰富的临床经验,但该病的治疗效果仍不尽人意,死亡率仍约为30%。坏死性筋膜炎很少出现明显的体征和症状,诊断延误增加死亡率。因此,成功的患者护理取决于医生的敏锐洞察力和怀疑指数。及时的手术清创、静脉使用抗生素、液体和电解质管理以及镇痛是主要治疗方法。辅助使用克林霉素、高压氧治疗和静脉注射免疫球蛋白常用于坏死性筋膜炎的治疗,但其疗效尚未得到严格证实。对坏死性筋膜炎发病机制的深入了解揭示了合理设计治疗方法以改善发病率和死亡率的新靶点。